Data from The dialysis outcomes and practice patterns study validate an association between high intravenous iron doses and mortality

Kidney International

Volumn 87, Issue 1, 2015, Pages 162-168

  Bailie, George R ^a   Larkina, Maria ^b   Goodkin, David A ^b   Li, Yun ^b,c   Pisoni, Ronald L ^b   Bieber, Brian ^b   Mason, Nancy ^c   Tong, Lin ^b   Locatelli, Francesco ^d   Marshall, Mark R ^e   Inaba, Masaaki ^f   Robinson, Bruce M ^b,c  

^a ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^b ARBOR RESEARCH COLLABORATIVE FOR HEALTH   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

^d A MANZONI HOSPITAL   (Italy)

^e UNIVERSITY OF AUCKLAND   (New Zealand)

^f OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Dialysis; Erythropoietin; Hemodialysis; Hemodialysis adequacy; Hospitalization; Mortality

Indexed keywords

FERRITIN; IRON;

ADULT; ANEMIA; ARTICLE; BODY WEIGHT; CARDIOVASCULAR DISEASE; DIALYSIS; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG INDICATION; FEMALE; FERRITIN BLOOD LEVEL; FOLLOW UP; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MALE; MEDICAL PRACTICE; MORTALITY; PRESCRIPTION; RISK ASSESSMENT; TREATMENT DURATION; TREATMENT OUTCOME; VALIDATION STUDY; ANEMIA, IRON-DEFICIENCY; HEMODIALYSIS; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; PROSPECTIVE STUDY; REPRODUCIBILITY;

ADMINISTRATION, INTRAVENOUS; ANEMIA, IRON-DEFICIENCY; FEMALE; HUMANS; IRON; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RENAL DIALYSIS; REPRODUCIBILITY OF RESULTS;

EID: 84920107364     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2014.275     Document Type: Article

References (50)

1. Van Buren P, Velez RL, Variri ND et al. Iron overdose: a contributor to adverse outcomes in randomized trials of anemia correction in CKD. Int Urol Nephrol 2012; 44: 499-507.
2. DOPPS Practice Monitor: Emerging Trends. August 2012. Available at http://www.dopps.org/DPM/. Accessed 10 December 2012.
3. US Renal Data System, USRDS 2010 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in The United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, USA 2010; http://www.usrds.org/2012/pdf/v2-00precis-12.pdf. Accessed 10 December 2012.
4. Hasegawa T, Bragg-Gresham JL, Pisoni RL et al. Changes in anemia management and hemoglobin levels following revision of a bundling policy to incorporate recombinant human erythropoietin. Kidney Int 2011; 79: 340-346.
5. McFarlane PA, Pisoni RL, Eichleay MA et al. International trends in erythropoietin use and hemoglobin levels in hemodialysis patients. Kidney Int 2010; 78: 215-223.
6. Freburger JK, Ng LJ, Bradbury BD et al. Changing patterns of anemia management in US hemodialysis patients. Am J Med 2012; 125: 906-914.
7. United States Food and Drug Administration. Public Health Advisory: erythropoiesis-stimulating agents (ESAs). Available at http://wwwfda.gov/ForConsumers/ByAudience/ForPatientAdvocates/HIVandAIDSActivities/ucm124262.htm. Accessed 1 April 2013.
8. Besarab A, Kaiser JW, Frinak S. A study of parenteral iron regimens in hemodialysis patients. Am J Kidney Dis 1999; 34: 21-28.
9. Charytan C, Levin N, Al-Saloum M et al. Efficacy and safety of iron sucrose for iron deficiency in patients with dialysis-associated anemia: North American clinical trial. Am J Kidney Dis 2001; 37: 300-307.
10. Provenzano R, Schiller B, Rao M et al. Ferumoxytol as an intravenous iron replacement therapy in hemodialysis patients. Clin J Am Soc Nephrol 2009; 4: 386-393.
11. Fishbane S, Frei GL, Maesaka J. Reduction in recombinant human erythropoietin doses by The use of chronic intravenous iron supplementation. Am J Kidney Dis 1995; 26: 41-46.
12. Wysowski DK, Swartz L, Borders-Hemphill BV et al. Use of parenteral iron products and serious anaphylactic-type reactions. Am J Hematol 2010; 85: 650-654.
13. Sirken G, Raja R, Rizkala AR. Association of different intravenous iron preparations with risk of bacteremia in maintenance hemodialysis patients. Clin Nephrol 2006; 66: 348-356.
14. Vaziri ND. Epidemic of iron overload in dialysis population caused by intravenous iron products: a plea for moderation. Am J Med 2012; 125: 951-952.
15. Kuo KL, Hung SC, Sei YH et al. Intravenous iron exacerbates oxidative DNA damage in peripheral blood lymphocytes in chronic hemodialysis patients. J Am Soc Nephrol 2008; 19: 1817-1826.
16. Kamanna VS, Ganji SH, Shelkovnikov S et al. Iron sucrose promotes endothelial injury and dysfunction and monocyte adhesion/infiltration. Am J Nephrol 2012; 35: 114-119.
17. Stefansson BV, Haraldsson B, Nilsson U. Acute oxidative stress following intravenous iron injection in patients on chronic hemodialysis: a comparison of iron-sucrose and iron-dextran. Nephron Clin Pract 2011; 118: c249-c256.
18. Brookhart MA, Schneeweiss S, Avorn J et al. Comparative mortality risk of anemia management practices in incident hemodialysis patients. JAMA 2010; 303: 857-864.
19. Feldman HI, Joffe M, Robinson B et al. Administration of parenteral iron and mortality among hemodialysis patients. J Am Soc Nephrol 2004; 15: 1623-1632.
20. Kalantar-Zadeh K, Regidor DL, McAllister CJ et al. Time-dependent associations between iron and mortality in hemodialysis patients. J Am Soc Nephrol 2005; 16: 3070-3080.
21. Bailie GR, Larkina M, Goodkin DA et al. Variation in intravenous iron use internationally and over time: The Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 2013; 28: 2570-2579.
22. Anaemia management in chronic kidney disease. Rapid update 2011. National Clinical Guideline Centre, London, 2011. Available at http://guidance.nice.org.uk/CG114/Guidance/pdf/English. Accessed 23 February 2011.
23. Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group. KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int Suppl 2012; 2: 279-335.
24. Anker SD, Colet JC, Filippatos G et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 2009; 361: 2436-2448.
25. Khalafallah AA, Dennis AE, Ogden K et al. Three-year follow-up of a randomised clinical trial of intravenous vs. oral iron for anaemia in pregnancy. BMJ Open 2012; 2: pii e000998.
26. Brookhart MA, Freburger JK, Ellis AR et al. Infection risk with bolus vs. maintenance iron supplementation in hemodialysis patients. J Am Soc Nephrol 2013; 24: 1151-1158.
27. Rostoker G, Griuncelli M, Loridon C et al. Hemodialysis-associated hemosiderosis in The era of erythropoiesis-stimulating agents: a MRI study. Am J Med 2012; 125: 991-999.
28. Canavese C, Bergamo D, Ciccone G et al. Validation of serum ferritin values by magnetic suspectometry in predicting iron overload in dialysis patients. Kidney Int 2004; 65: 1091-1098.
29. Neven E, De Schutter DM, Behets GJ et al. Iron and vascular calcification. Is there a link? Nephrol Dial Transplant 2011; 26: 1137-1145.
30. Coyne DW, Kapoian T, Suk IW et al. Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of The Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study. J Am Soc Nephrol 2007; 18: 975-984.
31. Munoz M, Garcia-Erce JA, Remacha AF. Disorders of iron metabolism. Part II: iron deficiency and iron overload. J Clin Pathol 2011; 64: 287-296.
32. Fleming RE, Ponka P. Iron overload in human disease. N Engl J Med 2012; 366: 348-359.
33. Nakanishi T, Kuragano T, Kaibe S et al. Should we reconsider iron administration based on prevailing ferritin and hepcidin concentrations? Clin Exp Nephrol 2012; 16: 819-826.
34. Kooi ME, Cappendijk VC, Cleutjens KB et al. Accumulation of ultrasmall superparamagnetic particles of iron oxide in human atherosclerotic plaques can be detected by in vivo magnetic resonance imaging. Circulation 2003; 107: 2453-2458.
35. Geisser P, Baer M, Schaub E. Structure/histotoxicity relationship of parenteral iron products. Arzneimittelforschung 1992; 42: 1439-1452.
36. Danielson BG. Structure, chemistry and pharmacokinetics of intravenous iron products. J Am Soc Nephrol 2004; 15: S93-S98.
37. Toblli JE, Cao G, Oliveri L et al. Comparison of The renal, cardiovascular and hepatic toxicity data of original intravenous iron compounds. Nephrol Dial Transplant 2010; 25: 3631-3640.
38. National Kidney Foundation. NKF-KDOQI clinical practice guidelines for anemia of chronic kidney disease: update 2000. Available at http://www.kidney.org/professionals/kdoqi/guidelines-updates/doqi-uptoc.html#an. Accessed 18 February 2013.
39. Young EW, Goodkin DA, Mapes DL et al. The Dialysis Outcomes and Practice Patterns Study: an international hemodialysis study. Kidney Int 2000; 57: S74-S81.
40. Pisoni RL, Gillespie BW, Dickinson DM et al. The Dialysis Outcomes and Practice Patterns Study (DOPPS): design, data elements, and methodology. Am J Kidney Dis 2004; 44(Suppl 2): 7-15.
41. Angrist JD, Imbens GW, Rubin DB. Identification of causal effects using instrumental variables. J Am Stat Assoc 1996; 91: 444-455.
42. Wooldridge JM, Chapter 15. Introductory Econometrics: A Modern Approach, 4th ed. Cengage Learning, USA, 2002.
43. Newhouse JP, McClellan M. Econometrics in outcomes research: The use of instrumental variables. Annu Rev Public Health 1998; 19: 17-34.
44. Greenland S. An introduction to instrumental variables for epidemiologists. Int J Epidemiol 2000; 29: 722-729.
45. Pisoni RL, Arrington CJ, Albert JM et al. Facility hemodialysis vascular access use and mortality in countries participating in DOPPS: An instrumental variable analysis. Am J Kidney Dis 2009; 53: 475-491.
46. Stock JH, Wright JH, Yogo M. A survey of weak instruments and weak identification in generalized method of moments. J Bus Econ Stat 2002; 20: 518-529.
47. Burgess S, Thompson SG. CRP CHD Genetics Collaboration. Avoiding bias from weak instruments in Mendelian randomization studies. Int J Epidemiol 2011; 40: 755-764.
48. Lopes AA, Tong L, Thumma J et al. Phosphate binder use and mortality among hemodialysis patients in The Dialysis Outcomes and Practice Patterns Study (DOPPS): evaluation of possible confounding by nutritional status. Am J Kidney Dis 2012; 60: 90-101.
49. Tentori F, Zhang J, Li Y et al. Longer dialysis session length is associated with better intermediate outcomes and survival among patients on in-center three times per week hemodialysis: results from The Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 2012; 27: 4180-4188.
50. Raghunathan TE, Solenberger PW, Van Hoewyk J. IVEware: imputation and variance estimation software. Ann Arbor, MI: Institute for Social Research, University of Michigan 1998; http://www.isr.umich.edu/src/smp/ive.